Arrowhead Presents Positive New Phase 1/2 Clinical Data on Cardiometabolic Candidates ARO-APOC3 and ARO-ANG3 at European Society of Cardiology Congress 2020
ARO-APOC3 Presentation Details:
- Title: RNA Interference Targeting Apolipoprotein C-3 with ARO-APOC3 in Healthy Volunteers Mimics Lipid and Lipoprotein Findings Seen in Subjects with Inherited Apolipoprotein C-3 Deficiency
-
Authors:
Christian Schwabe , et al. -
Presenter:
Christie M. Ballantyne - Type: Oral Presentation
-
Date and Time:
August 31, 2020 , at10:50 CEST
Key points presented include the following:
-
In normal volunteers, repeat doses of ARO-APOC3, an investigational RNAi therapeutic that silences APOC3 mRNA, resulted in:
- Reduction in APOC3
-
Maximal mean fasting lipid, lipoprotein, and apolipoprotein changes of:
- -75% for triglycerides (TG)
- -25% for low-density lipoprotein cholesterol (LDL-C)
- -33% for apolipoprotein B (ApoB)
- +75% for high-density lipoprotein cholesterol (HDL-C)
- ARO-APOC3 had a favorable safety and tolerability profile
- APOC3 inhibition produced expected favorable lipid changes, with reduced TG and LDL-C and increased HDL-C
ARO-ANG3 Presentation Details:
- Title: RNAi Inhibition of Angiopoietin-like Protein 3 (ANGPTL3) with ARO-ANG3 Mimics the Lipid and Lipoprotein Profile of Familial Combined Hypolipidemia
-
Authors:
Gerald F. Watts , et al. -
Presenter:
Gerald F. Watts - Type: Oral Presentation
-
Date and Time:
August 31, 2020 , at11:00 CEST
Key points presented include the following:
-
In normal volunteers, repeat doses of ARO-ANG3, an investigational RNAi therapeutic that silences ANGPTL3 mRNA, demonstrated:
- Dose-dependent reduction in fasting ANGPTL3
-
Maximal mean reductions in fasting lipid, lipoprotein, and apolipoprotein concentrations of:
- -71% in TG
- -50% in LDL-C
- -42% in ApoB
- -34% in non-HDL-C
- -47% in HDL-C
- Lipid, lipoprotein, and apolipoprotein reductions sustained to week 16
- ARO-ANG3 had a favorable safety and tolerability profile
- ANGPTL3 inhibition has the potential to treat mixed dyslipidemia and decrease residual risk in patients with cardiovascular disease on guideline-recommended standard of care
A copy of the presentation materials may be accessed on the Events and Presentations page under the Investors section of the Arrowhead website.
About
For more information, please visit www.arrowheadpharma.com, or follow us on Twitter @ArrowheadPharma. To be added to the Company's email list and receive news directly, please visit http://ir.arrowheadpharma.com/email-alerts.
Safe Harbor Statement under the Private Securities Litigation Reform Act:
This news release contains forward-looking statements within the meaning of the "safe harbor" provisions of the Private Securities Litigation Reform Act of 1995. These statements are based upon our current expectations and speak only as of the date hereof. Our actual results may differ materially and adversely from those expressed in any forward-looking statements as a result of various factors and uncertainties, including the safety and efficacy of our product candidates, the duration and impact of regulatory delays in our clinical programs, our ability to finance our operations, the likelihood and timing of the receipt of future milestone and licensing fees, the future success of our scientific studies, our ability to successfully develop and commercialize drug candidates, the timing for starting and completing clinical trials, rapid technological change in our markets, and the enforcement of our intellectual property rights. Our most recent Annual Report on Form 10-K and subsequent Quarterly Reports on Form 10-Q discuss some of the important risk factors that may affect our business, results of operations and financial condition. We assume no obligation to update or revise forward-looking statements to reflect new events or circumstances.
Source:
View source version on businesswire.com: https://www.businesswire.com/news/home/20200831005208/en/
626-304-3400
ir@arrowheadpharma.com
Investors:
212-915-2578
britchie@lifesciadvisors.com
www.lifesciadvisors.com
Media:
646-751-4361
jo@lifescicomms.com
www.lifescicommunications.com
Source: